149 related articles for article (PubMed ID: 35868355)
1. Elevated 8-isoprostane concentration is associated with thromboembolic events in patients with atrial fibrillation.
Mołek P; Chmiel J; Ząbczyk M; Malinowski KP; Natorska J; Undas A
Int J Cardiol; 2022 Oct; 365():1-7. PubMed ID: 35868355
[TBL] [Abstract][Full Text] [Related]
2. Altered fibrin clot properties are associated with the progression of chronic kidney disease in atrial fibrillation.
Heleniak Z; Matusik PT; Undas A
Thromb Res; 2024 Apr; 236():14-21. PubMed ID: 38387299
[TBL] [Abstract][Full Text] [Related]
3. Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: association with thrombin generation, endothelial injury and platelet activation.
Drabik L; Wołkow P; Undas A
Thromb Res; 2015 Aug; 136(2):408-14. PubMed ID: 26048399
[TBL] [Abstract][Full Text] [Related]
4. Clot Lysis Time Predicts Stroke During Anticoagulant Therapy in Patients with Atrial Fibrillation.
Drabik L; Konieczyńska M; Undas A
Can J Cardiol; 2020 Jan; 36(1):119-126. PubMed ID: 31740169
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
[TBL] [Abstract][Full Text] [Related]
6. Markers of NET formation and stroke risk in patients with atrial fibrillation: association with a prothrombotic state.
Mołek P; Ząbczyk M; Malinowski KP; Natorska J; Undas A
Thromb Res; 2022 May; 213():1-7. PubMed ID: 35276507
[TBL] [Abstract][Full Text] [Related]
7. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients.
Roldán V; Marín F; Muiña B; Torregrosa JM; Hernández-Romero D; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2011 Jun; 57(25):2496-504. PubMed ID: 21497043
[TBL] [Abstract][Full Text] [Related]
8. Elevated NT-proBNP is associated with unfavorably altered plasma fibrin clot properties in atrial fibrillation.
Matusik PT; Matusik PS; Kornacewicz-Jach Z; Małecka B; Ząbek A; Undas A
Int J Cardiol; 2017 Sep; 243():244-250. PubMed ID: 28571619
[TBL] [Abstract][Full Text] [Related]
9. Prothrombotic State in Atrial Fibrillation Patients With One Additional Risk Factor of the CHA
Głowicki B; Matusik PT; Plens K; Undas A
Can J Cardiol; 2019 May; 35(5):634-643. PubMed ID: 30955928
[TBL] [Abstract][Full Text] [Related]
10. Prothrombotic plasma fibrin clot phenotype is associated with spontaneous echo contrast in atrial fibrillation: The role of protein carbonylation.
Słaboszewski M; Kolec R; Paszek E; Baran M; Undas A
Thromb Res; 2024 Jun; 240():109065. PubMed ID: 38908317
[TBL] [Abstract][Full Text] [Related]
11. Fibrin Clot Permeability as a Predictor of Stroke and Bleeding in Anticoagulated Patients With Atrial Fibrillation.
Drabik L; Wołkow P; Undas A
Stroke; 2017 Oct; 48(10):2716-2722. PubMed ID: 28904234
[TBL] [Abstract][Full Text] [Related]
12. Thromboembolic events are associated with prolonged clot lysis time in patients with permanent atrial fibrillation.
Ząbczyk M; Majewski J; Lelakowski J
Pol Arch Med Wewn; 2011 Nov; 121(11):400-7. PubMed ID: 22064373
[TBL] [Abstract][Full Text] [Related]
13. Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation.
Matusik PT; Małecka B; Lelakowski J; Undas A
Clin Res Cardiol; 2020 Apr; 109(4):426-434. PubMed ID: 31280356
[TBL] [Abstract][Full Text] [Related]
14. Prothrombotic State in Patients With a Left Atrial Appendage Thrombus of Unknown Origin and Cerebrovascular Events.
Meus R; Son M; Sobczyk D; Undas A
Stroke; 2016 Jul; 47(7):1872-8. PubMed ID: 27301942
[TBL] [Abstract][Full Text] [Related]
15. Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3days of treatment: Relation to coagulation factors and thrombin generation.
Ząbczyk M; Majewski J; Karkowski G; Malinowski KP; Undas A
Thromb Res; 2015 Oct; 136(4):832-8. PubMed ID: 26319777
[TBL] [Abstract][Full Text] [Related]
16. [A comparison of CAS risk model and CHA
Deng JL; He L; Jiang C; Lai YW; Long DY; Sang CH; Jia CQ; Feng L; Li X; Ning M; Hu R; Dong JZ; Du X; Tang RB; Ma CS
Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Sep; 50(9):888-894. PubMed ID: 36096706
[No Abstract] [Full Text] [Related]
17. Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger.
Ząbczyk M; Blombäck M; Majewski J; Karkowski G; Wallen HN; Undas A; He S
Thromb Haemost; 2015 Apr; 113(4):851-61. PubMed ID: 25518887
[TBL] [Abstract][Full Text] [Related]
18. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in secondary stroke and systemic embolism prevention.
Gorczyca I; Michalska A; Chrapek M; Jelonek O; Wałek P; Wożakowska-Kapłon B
Cardiol J; 2021; 28(6):896-904. PubMed ID: 31313276
[TBL] [Abstract][Full Text] [Related]
19. Altered fibrin clot properties and fibrinolysis in patients with atrial fibrillation: practical implications.
Undas A
Europace; 2020 Feb; 22(2):185-194. PubMed ID: 31625555
[TBL] [Abstract][Full Text] [Related]
20. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.
Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB
Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
